Hutchison China MediTech Ltd.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment covers all activities related to oncology/immunology including sales, marketing, manufacturing and research and development with respect to drugs and drug candidates. The Other Ventures segment includes all other HUTCHMED businesses. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs

Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs

Chi-Med Announces Proposed Public Offering of ADSs

Hutchison China MediTech Limited (HCM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Hutchison China MediTech

As of late, it has definitely been a great time to be an investor in Hutchison China MediTech.

Will Hutchison China MediTech Continue to Surge Higher?

LONDON, Jan.  20, 2020  (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the independent Data Monitoring Committee (“IDMC”) of the Phase III pivotal study of  s urufatinib in  a dvanced  n euro e ndocrine  t umors – p ancreatic (“SANET-p”) has completed a pre-planned interim analysis.  The IDMC recommended that the study stops early as the pre-defined primary endpoint of progression free survival (“PFS”) had already been met.

Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early

Does Hutchison China MediTech (HCM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Hutchison China MediTech (HCM) Is Up 0.6% in One Week: What You Should Know

LONDON, Jan.  13, 2020  (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) has initiated a Phase II study in China of surufatinib in combination with Tuoyi (toripalimab) in patients with advanced solid tumors. This follows the recent completion of the Phase I dose finding study and successful establishment of the Phase II combination dosing regimen for surufatinib and Tuoyi.

Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors

LONDON, Jan.  06, 2020  (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 38th Annual JP Morgan Healthcare Conference on Wednesday, January 15, 2020 at 1:00pm PST in San Francisco, CA. 

Chi-Med to Present at the 38th Annual JP Morgan Healthcare Conference

LONDON, Dec.  20, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) today announces that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (“NMPA”) has granted Priority Review status to the New Drug Application (“NDA”) for surufatinib for the treatment of patients with advanced non-pancreatic neuroendocrine tumors (“NET”).

Chi-Med’s New Drug Application for Surufatinib in Non-Pancreatic Neuroendocrine Tumors Granted Priority Review in China

LONDON, Nov.  28, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Elunate® (fruquintinib capsules), its national class 1 targeted anticancer drug for the treatment of patients with advanced colorectal cancer (“CRC”), has been included in the updated National Reimbursement Drug List (“NRDL”) released by China’s National Healthcare Security Administration (“NHSA”). 

Chi-Med’s Elunate® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China

LONDON, Nov.  25, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug designation to surufatinib for the treatment of pancreatic neuroendocrine tumors (“NET”).

Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors

LONDON, Nov.  11, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) today announces that its New Drug Application (“NDA”) for surufatinib for the treatment of patients with advanced non-pancreatic neuroendocrine tumors (“NET”) has been accepted for review by the China National Medical Products Administration.

Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors

LONDON, Oct.  17, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) today highlighted the publication of results from the Phase II VIKTORY (targeted agent e V aluation  I n gastric cancer bas K e T  K OR ea stud Y ) trial in   Cancer Discovery  , a journal of the American Association of Cancer Research1. The principal study investigator was Dr. Jeeyun Lee, Associate Professor at the Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 

Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers

SUZHOU, China and LONDON, Oct.  10, 2019  (GLOBE NEWSWIRE) -- Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) and Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the expansion of their global collaboration agreement to evaluate the safety and efficacy of Innovent’s Tyvyt® (sintilimab injection), a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody, in combination with Chi-Med’s surufatinib, a novel inhibitor of vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor 1 (FGFR1) and colony stimulating factor-1 receptor (CSF-1R), in patients with advanced solid tumors. The expansion builds on the existing global collaboration agreement between the two companies on sintilimab in combination with Chi-Med’s highly selective VEGFR inhibitor, fruquintinib.

Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

LONDON, Oct.  04, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with relapsed or refractory lymphoma.  The first patient was dosed on September 26, 2019 in the U.S.

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma

CK Hutchison Holdings Ltd

CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term

Hutchison China MediTech has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Hutchison China MediTech Solutions Enters Oversold Territory

– Surufatinib achieved primary endpoint, reducing the risk of progression or death by 67% in patients with non-pancreatic neuroendocrine tumors (“NET”) in the Phase III SANET-ep study –

Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting

– Late-Breaking Abstract of the positive SANET-ep Phase III trial of surufatinib in patients with non-pancreatic neuroendocrine tumors (“NET”) to be presented –

Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting

LONDON, Sept.  18, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) shares additional analyses from three completed and ongoing clinical studies of fruquintinib and savolitinib at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (“CSCO”) on September 18 to 22, 2019 in Xiamen, China.

Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting

LONDON, Sept.  03, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11, 2019 at 9:55 am (EDT) in New York, NY. 

Chi-Med to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

LONDON, Sept.  03, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-689, its novel, highly selective and potent small molecule phosphoinositide-3 kinase delta isoform (“PI3Kδ”) inhibitor, in patients with relapsed or refractory lymphoma.  The first patient was dosed on August 26, 2019 in the U.S.

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma

LONDON, Aug.  23, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with immune thrombocytopenia (“ITP”), an autoimmune disorder that can lead to increased risk of bleeding. The first ITP patient was dosed on August 12, 2019 in China.

Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in China

Hutchison China MediTech Ltd (HCM) CEO Christian Hogg on Q2 2019 Results - Earnings Call Transcript

News for Hutchison China MediTech Ltd. Stock (HCM)